Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p17454 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/17454 |
| Access Level: | acceso abierto |
| id |
ES_a775a2f5d516349e097f0eebb030dc72 |
|---|---|
| oai_identifier_str |
oai:incliva.fundanetsuite.com:p17454 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupSargas, ClaudiaAyala, RosaLarrayoz, Maria JChillon, Maria CRodriguez-Arboli, EduardoBilbao, CristinaPrados de la Torre, EstherMartinez-Cuadron, DavidRodriguez-Veiga, RebecaBoluda, BlancaGil, CristinaBernal, TeresaBergua, JuanAlgarra, LorenzoTormo, MarMartinez-Sanchez, PilarSoria, ElenaSerrano, JosefinaAlonso-Dominguez, Juan MGarcia, RaimundoAmigo, Maria LuzHerrera-Puente, PilarSayas, Maria JLavilla-Rubira, EsperanzaMartinez-Lopez, JoaquinCalasanz, Maria JGarcia-Sanz, RamonPerez-Simon, Jose AGomez Casares, Maria TSanchez-Garcia, JoaquinBarragan, EvaMontesinos, PauNext-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged >= 65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with >= 2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 +/- complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.SPRINGERNATURE2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/17454Blood Cancer JournalISSN: 20445385reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p174542026-06-07T16:35:31Z |
| dc.title.none.fl_str_mv |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| title |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| spellingShingle |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group Sargas, Claudia |
| title_short |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| title_full |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| title_fullStr |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| title_full_unstemmed |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| title_sort |
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
| dc.creator.none.fl_str_mv |
Sargas, Claudia Ayala, Rosa Larrayoz, Maria J Chillon, Maria C Rodriguez-Arboli, Eduardo Bilbao, Cristina Prados de la Torre, Esther Martinez-Cuadron, David Rodriguez-Veiga, Rebeca Boluda, Blanca Gil, Cristina Bernal, Teresa Bergua, Juan Algarra, Lorenzo Tormo, Mar Martinez-Sanchez, Pilar Soria, Elena Serrano, Josefina Alonso-Dominguez, Juan M Garcia, Raimundo Amigo, Maria Luz Herrera-Puente, Pilar Sayas, Maria J Lavilla-Rubira, Esperanza Martinez-Lopez, Joaquin Calasanz, Maria J Garcia-Sanz, Ramon Perez-Simon, Jose A Gomez Casares, Maria T Sanchez-Garcia, Joaquin Barragan, Eva Montesinos, Pau |
| author |
Sargas, Claudia |
| author_facet |
Sargas, Claudia Ayala, Rosa Larrayoz, Maria J Chillon, Maria C Rodriguez-Arboli, Eduardo Bilbao, Cristina Prados de la Torre, Esther Martinez-Cuadron, David Rodriguez-Veiga, Rebeca Boluda, Blanca Gil, Cristina Bernal, Teresa Bergua, Juan Algarra, Lorenzo Tormo, Mar Martinez-Sanchez, Pilar Soria, Elena Serrano, Josefina Alonso-Dominguez, Juan M Garcia, Raimundo Amigo, Maria Luz Herrera-Puente, Pilar Sayas, Maria J Lavilla-Rubira, Esperanza Martinez-Lopez, Joaquin Calasanz, Maria J Garcia-Sanz, Ramon Perez-Simon, Jose A Gomez Casares, Maria T Sanchez-Garcia, Joaquin Barragan, Eva Montesinos, Pau |
| author_role |
author |
| author2 |
Ayala, Rosa Larrayoz, Maria J Chillon, Maria C Rodriguez-Arboli, Eduardo Bilbao, Cristina Prados de la Torre, Esther Martinez-Cuadron, David Rodriguez-Veiga, Rebeca Boluda, Blanca Gil, Cristina Bernal, Teresa Bergua, Juan Algarra, Lorenzo Tormo, Mar Martinez-Sanchez, Pilar Soria, Elena Serrano, Josefina Alonso-Dominguez, Juan M Garcia, Raimundo Amigo, Maria Luz Herrera-Puente, Pilar Sayas, Maria J Lavilla-Rubira, Esperanza Martinez-Lopez, Joaquin Calasanz, Maria J Garcia-Sanz, Ramon Perez-Simon, Jose A Gomez Casares, Maria T Sanchez-Garcia, Joaquin Barragan, Eva Montesinos, Pau |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| description |
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged >= 65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with >= 2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 +/- complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://incliva.portalinvestigacion.com/publicaciones/17454 |
| url |
https://incliva.portalinvestigacion.com/publicaciones/17454 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
SPRINGERNATURE |
| publisher.none.fl_str_mv |
SPRINGERNATURE |
| dc.source.none.fl_str_mv |
Blood Cancer Journal ISSN: 20445385 reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname:INCLIVA |
| instname_str |
INCLIVA |
| reponame_str |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| collection |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869415779991027712 |
| score |
15,812429 |